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Background: Several Echinacea species have been used as nutraceuticals or botanical drugs for
“immunostimulation”, but scientific evidence supporting their therapeutic use is still controversial. In this study, a
phytocompound mixture extracted from the butanol fraction (BF) of a stem and leaf (S+L) extract of E. purpurea
([BF/S+L/Ep]) containing stringently defined bioactive phytocompounds was obtained using standardized and
published procedures. The transcriptomic and proteomic effects of this phytoextract on mouse bone marrow-
derived dendritic cells (BMDCs) were analyzed using primary cultures.
Results: Treatment of BMDCs with [BF/S+L/Ep] did not significantly influence the phenotypic maturation activity of
dendritic cells (DCs). Affymetrix DNA microarray and bioinformatics analyses of genes differentially expressed in DCs
treated with [BF/S+L/Ep] for 4 or 12 h revealed that the majority of responsive genes were related to cell adhesion
or motility (Cdh10, Itga6, Cdh1, Gja1 and Mmp8), or were chemokines (Cxcl2, Cxcl7) or signaling molecules (Nrxn1,
Pkce and Acss1). TRANSPATH database analyses of gene expression and related signaling pathways in treated-DCs
predicted the JNK, PP2C-a, AKT, ERK1/2 or MAPKAPK pathways as the putative targets of [BF/S+L/Ep]. In parallel,
proteomic analysis showed that the expressions of metabolic-, cytoskeleton- or NF-B signaling-related proteins
were regulated by treatment with [BF/S+L/Ep]. In vitro flow cytometry analysis of chemotaxis-related receptors and
in vivo cell trafficking assay further showed that DCs treated with [BF/S+L/Ep] were able to migrate more effectively
to peripheral lymph node and spleen tissues than DCs treated as control groups.
Conclusion: Results from this study suggest that [BF/S+L/Ep] modulates DC mobility and related cellular
physiology in the mouse immune system. Moreover, the signaling networks and molecules highlighted here are
potential targets for nutritional or clinical application of Echinacea or other candidate medicinal plants.
Background
Dendritic cells (DCs) participate in a wide spectrum of
immune cell functions including antigen-presentation,
phagocytic activity and T cell-mediated immunities [1].
Currently, a number of experimental approaches are
being evaluated to develop DC-based immunotherapy
and gene-based tumor vaccine strategies to elicit specific
immunities against specific cancers (e.g., prostate cancer)
or infectious diseases [2-8]. DCs can capture and take up
antigens present in peripheral tissue and transport them
to primary and secondary lymphoid tissue for presenta-
tion to T cells [4]. Therefore, extensive research regard-
ing cell migration, homing, and the cellular fate of DCs
in various tissue systems is considered a critical issue.
Research on mouse bone marrow-derived dendritic cells
(BMDCs) has shown the importance of using experimen-
tal models for research into DC-based therapeutics [5-8].
We recently reported the effect and possible application
of Echinacea purpurea (Ep) phytocompounds as
immune-modifiers for human DCs using functional
genomic and proteomic approaches [9,10]. Here, we
extended our study to the mouse DC system, and investi-
gated the effects of the chemically defined Ep phyto-
extracts (BF/S+L/Ep) on immunomodulatory activity and
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and in vivo conditions.
Since the 1990s, the use of Echinacea spp. as a medic-
inal plant or food supplement has gained popularity in
the USA and Europe [11,12], and is now even recognized
in Asia (e.g., China). The possible effects of Echinacea
spp. extracts on in vitro activation of macrophages, nat-
ural killer (NK) cells, and other immune cell types
[13-15], and on stimulating the expression of cytokines
such as tumor necrosis factor-alpha (TNF-a), interferon,
interleukin-1 and interleukin-6 [16] have all been
reported. In vivo studies showed that treatment with
Echinacea extracts can increase white blood cell popula-
tions in the circulation system [17], and enhance phago-
cytosis [18]. E. purpurea extracts have been evaluated in
clinical trials for efficiency against the common cold, but
the controversial results are continuously disputed
[9,10,12,19,20]. To systemically assess the immunomodu-
latory effects on mouse DCs in vivo,w ee m p l o y e da
chemically defined Echinacea purpurea extract, termed
[BF/S+L/Ep], containing hypoxanthine, chlorogenic acid,
caffeic acid, cichoric acid, quercetin-3-O-rhamnosyl-
(1®6)-galactoside, kaempferol-3-O-rhamnosyl-(1®6)-
galactoside and rutin [10].
Profiling of specific and global gene expression patterns
by DNA microarray analysis coupled with proteomic ana-
lysis provides a useful approach for the investigation of
complex biological phenomena [21,22] as we have pre-
viously shown for immune cell systems [9,10]. In this
study, we used a network knowledge-based approach to
analyze genome-wide transcriptome activity in vitro and
in vivo, for correlation to specific proteome activities and
special functional phenotypes in mouse immature
BMDCs, in response to treatment with [BF/S+L/Ep]. Our
findings suggest that [BF/S+L/Ep] was able to modulate
cell adhesion-, cell mobility-, cytokine- and NF-Bs i g -
naling-related activities in primary cultures of mouse
DCs. In vivo trafficking experiments using ex vivo-treated
DCs demonstrated that [BF/S+L/Ep] could enhance the
mobility of DCs to target specific lymphoid organs in test
mouse. Moreover, bioinformatics studies allowed us to
predict several candidate target molecules for the future
translational studies of this or other phytocompound
mixtures. The significance of our findings and potential
application to future studies of human DCs are discussed.
Results
1. Expression of DC markers in response to treatment
with [BF/S+L/Ep]
Initially, we set out to examine whether [BF/S+L/Ep]
could influence the maturation activity of BMDCs.
Mouse bone marrow cells were isolated and cultured for
9 days in RPMI-1640 supplemented with 200 U/mL GM-
CSF. DCs cultured in the presence of GM-CSF showed
the functional and phenotypic characteristics of the
immature stage and could be further differentiated
in vitro into mature DCs. LPS, at 1 μg/mL, was then used
to induce maturation of DCs. Some test cells were ana-
lyzed for the effect of [BF/S+L/Ep] for 24 h. Since con-
centrations of [BF/S+L/Ep] greater than 100 μg/mL were
slightly cytotoxic to test dendritic cells (evaluated using
MTT cell viability assays, data not shown), [BF/S+L/Ep]
was used at a concentration of 75 μg/mL, where no cyto-
toxicity was detectable. As seen in Figure 1, sharp peak
signals were obtained in flow cytometry analyses, demon-
strating that high quality DCs were routinely obtained.
Flow cytometry analysis ont h ee x p r e s s i o no fC D 4 0 ,
CD80, CD86, MHC class II and CD11c on BMDCs
showed that the control groupe x p r e s s e dl o w e rl e v e l so f
co-stimulatory and activation molecules than the LPS-
treated groups. There was no significant difference
between the DMSO-treated and [BF/S+L/Ep]-treated
groups (Figure 1). Compared with the LPS group,
BMDCs co-treated with 75 μg/ml [BF/S+L/Ep] and 1 μg/
mL LPS only showed a weak inhibition of CD40 at 24 h
post-LPS treatment, whereas expression of CD40, CD86,
MHC class II and CD11c were not significantly affected.
T h e s ed a t ai n d i c a t et h a t[ B F / S + L / E p ]d i dn o th a v eas i g -
nificant effect on the phenotypic maturation of mouse
BMDCs.
2. Differential gene expression in immature BMDCs as a
response to treatment with [BF/S+L/Ep]
We next investigated the expression of specific genes
related to the cellular biochemistry and physiology of
immature DCs. Affymetrix DNA microarray analyses
showed that, although the gene expression of the cell
surface markers tested above were not affected, a series
of other genes related to DC activities were affected by
75 μg/ml [BF/S+L/Ep]. Initial experimental setups using
biological sample replicates showed that our test cell
culture systems and experimental protocols, e.g., RNA
preparation, were highly reproducible and consistent,
e.g., Pearson’s Correlation values for test biological sam-
ple replicates were between 0.993 and 0.996 (Figure 2).
All genes identified from the raw data of our Affymetrix
gene chip analyses were subjected to a gene filtering
proctocol, using established statistics software (Spotfire),
to select and identify candidate differentially expressed
genes for further studies. We chose genes that scored
positive in at least 4 different chips and that had a coef-
ficient of variation (CV) of over 0.4. A total of 907 and
1256 genes had changed expression significantly by 4 h
and by 12 h post-treatment with [BF/S+L/Ep], respec-
tively. Among these, 172 and 264 genes respectively
were identified as immune-related genes (Table 1). For
up-regulated or down-regulated genes, only those genes
that showed at least a 2-fold change in RNA transcript
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for further analysis. Differences in expression level were
calculated by dividing the signal intensity values of
genes from [BF/S+L/Ep]-treated cells by the intensity
values of genes from the vehicle-treated (control) cells.
Overall, similar numbers of genes were up-regulated
and down-regulated after treatment with [BF/S+L/Ep]
(Table 1). The expression of 29 genes more than
doubled in [BF/S+L/Ep]-treated DCs, compared to vehi-
cle control, at 4 h post-treatment, and a group of 31
genes were up-regulated (i.e., ≥ 2-fold change) at 12 h
post-treatment. In contrast, 26 and 35 genes were
down-regulated (expression more than halved) in [BF/
S+L/Ep]-treated DCs at 4 h and 12 h post-treatment,
respectively (Table 1). It is important to note that two
different sets of 51 non-immune related genes were
highly affected at 4 h and 12 h time points (Table 1).
The relative changes in gene expression levels in [BF/
S+L/Ep]-treated DCs are shown in Table 2 and Table 3
for 4 h and 12 h treatments, respectively. The unknown
genes and sequences are not shown in these tables.
A number of genes that are reported to be differentially
expressed in defined immune responses were found to
have increased expression after treatment with [BF/
S+L/Ep] [10]. These genes include angiomotin (Amot),
chemokine (C-X-C motif) ligand 5 (Cxcl5), pro-platelet
basic protein (Cxcl7) and immunoresponsive gene 1 (Irg1)
which were up-regulated at 4 h post-treatment with
[BF/S+L/Ep], and other genes including cytotoxic T-
lymphocyte-associated protein 4 (Ctla4) and chemokine
(C-X-C motif) ligand 7 (Cxcl7) were strongly up-regulated
at 12 h post-treatment. Among them, Cxcl7 was up-
regulated at both 4 h and 12 h time points (Table 2 and 3).
In addition, the expression of DC surface marker genes,
such as Cd40, Cd80, Cd86, Mhc II and Cd11c, showed little
or no changes after [BF/S+L/Ep] treatment, confirming
our previous flow cytometric analysis (Figure 1).
A number of the responsive genes found here have not
previously been shown to be differentially expressed in
DCs. Some of these include specific cell surface mole-
cules related to cell adhesion or to regulation of cytoske-
leton molecules, such as cadherin 10 (Cdh10), cadherin 1
(Cdh1), integrin a6 (Itga6), neural cell adhesion molecule
2( Ncam2), microtubule-associated protein 9 (Mtap9),
Cd38, and gap junction protein alpha 1 (Gja1). RNA
transcript levels for genes encoding several secreted
Figure 1 Effects of E. purpurea tissue extract [BF/S+L/Ep] on expression of cell-surface markers in mouse bone marrow-derived
immature dendritic cells. DCs were examined for the expression of CD40, CD80, CD86, MHC class II and CD11c following [BF/S+L/Ep] for 24 hr
by flow-cytometry.
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Ep]. These genes include chemokine (C-X-C motif)
ligand 2 (Cxcl5), pro-platelet basic protein (chemokine
(C-X-C motif) ligand 7) (Cxcl7), acid phosphatase (Acpp),
chondroitin sulfate proteoglycan 2 (Cspg2), matrix metal-
lopeptidase 8 (Mmp8), and serpin peptidase inhibitor
(Serpinb2). In comparison, the expression of transcripts
encoding several enzymes fell after treatment with [BF/
S+L/Ep]. These genes included protein kinase C (Prkce),
acyl-CoA synthetase (Acss1), ST8 alpha-N-acetyl-
neuraminide alpha-2,8-sialyltransferase 6 (St8sia6), and
Src-like-adaptor (Sla). Moreover, the expression of
mRNAs encoding transcription factors or DNA binding
proteins localized in the nuclear compartment, such as
ankyrin repeat and SOCS box-containing 2 (Asb2)a n d
inhibitor of kappa light polypeptide gene enhancer in B-
cells (Ikbkg), were increased in [BF/S+L/Ep]-treated DCs,
and the expressions other transcription regulatory genes,
such as synaptonemal complex protein 1 (Sycp1), RNA
binding motif protein 14 (Rbm14), HECT domain con-
taining 1 (Huwe1) and SRY (sex determining region Y)-
box 6 (Sox) were decreased (Table 2 and 3).
3. Putative signaling networks involved in modulatory
effect of [BF/S+L/Ep] on iBMDCs
Functional genomics experimental approaches were
employed in our previous study on the modulatory effect
of Echinacea plant extracts on human DCs [9,10]. Using
the same defined phytocompound extracts here we ana-
lyzed the genome-wide transcriptional response in the
context of known functional activities and interrelation-
ships among specific protein molecules and/or different
cell phenotypes by using Ingenuity Systems, a structured
network knowledge-based approach, to provide insight
Figure 2 Correlation of biological sample replicates. A, DMSO (control) replicates (Affymetrix ID: 579, 580) after 4 h treatment. Pearson
correlation value: 0.99735. B, [BF/S+L/Ep] replicates (Affymetrix ID: 581, 582) after 4 h treatment. Pearson correlation value: 0.99303. C, [DMSO]
(control) replicates (Affymetrix ID: 583, 584) after 12 h treatment. Pearson correlation value: 0.99628. D, [BF/S+L/Ep] replicates (Affymetrix ID: 585,
586) after 12 h treatment. Pearson correlation value: 0.99631. Data analysis used Spotfire software. Pearson correlation value and number of
unchanged transcripts were calculated using GCOS software.
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to the body immune system. Figure 3A shows the
hypothetical or candidate networks revealed by clustering
analysis of representative genes involved in the BMDC
response to [BF/S+L/Ep] treatment. Apparent temporal
controls for coordination of specific gene expressions
were classified into three different functional groups: the
immune response related genes (Group 1); adhesion
molecules, cytoskeleton and cell movement-related genes
(Group 2); and the cell cycle, cell proliferation, and apop-
tosis-related genes (Group 3). These responses to treat-
ment with [BF/S+L/Ep] extract in iBMDCs may be
viewed as an integrated cell-wide response involving cell
trafficking, attachment, immunity and apoptosis.
To identify possible signal transduction pathways in
response to [BF/S+L/Ep] treatment, we analyzed, for
both the 4 h and 12 h treatments, the 37 up-regulated
genes using TRANSPATH software in the manner pre-
viously reported [9,10]. Signal transduction pathways
involving the CRBP1, AhR, APC and Cyr61 genes with a
≥ 2-fold change in expression level (Table 2) were pre-
dicted. Apparent signaling network and functional geno-
mic analyses suggest that treatment of DCs with [BF/
S+L/Ep] may activate the JNK, PP2C-a,A K T ,E R K 1 / 2
or MAPKAPK pathways, because expression of their
downstream genes were up-regulated (Figure 3B). For
those down-regulated genes, the TRANSPATH software
was not able to predict a matched upstream pathway.
Table 1 Changes in gene expression in BMDCs in response to treatment with [BF/S+L/Ep]












a 513 472 985 2.90
≥1.5 104 94 198 0.58
≥2
b 19 10 29 0.09
≥3 6 5 11 0.03




a 89 83 172 0.51
≥1.5 16 14 30 0.09
≥2
c 4 0 4 0.01






b-c 15 10 25 0.07
At 12 h:
Total Genes Significant
a 605 736 1341 3.94
≥1.5 128 132 260 0.76
≥2
d 21 18 39 0.11
≥3 6 5 11 0.03




a 144 120 264 0.78
≥1.5 27 19 46 0.14
≥2







d-e 19 18 37 0.11
aDifferentially expressed genes that are significant in [BF/S+L/Ep] vs. [DMSO] (control). Values of p ≤ 0.05 are considered to be significant. All relative differences
greater than 1.5 are significant.
bUp-regulated genes with at least a 2-fold change in the level of RNA transcript expression after 4 h treatment.
cUp-regulated immune-related genes with at least a 2-fold change after 4 h treatment.
dDown-regulated genes with at least a 2-fold change in the level of RNA transcript expression after 4 h treatment.
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Page 5 of 18Table 2 Up-regulation of genes in iBMDCs treated with [BF/S+L/Ep] for (A) 4 h or (B) 12 h compared to DMSO alone
Gene Name Accession Number Expression Ratio
a (+)/(-)
At 4 h:
Cluster 1 Adhesion molecules, Cytoskeleton, Cell movement
Ncam2 neural cell adhesion molecule 2 NM_010954 6.57
Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 NM_011111 4.50
Ikbkg inhibitor of kappa B kinase gamma NM_010547 2.03
Cluster 2 Immune response
Amot angiomotin NM_153319 2.48
Cxcl5 chemokine (C-X-C motif) ligand 5 NM_009141 8.63
Irg1 immunoresponsive gene 1 XM_127883 2.17
Cxcl7 chemokine (C-X-C motif) ligand 7 NM_023785 2.08
Cluster 3 Signal transmission, Transporter
Nrxn1 neurexin I Q9CS84 9.62
Sorbs1 sorbin and SH3 domain containing 1 NM_009166 3.70
Ahrr aryl-hydrocarbon receptor repressor NM_009644 2.37
Abce1 ATP-binding cassette, sub-family E (OABP), member 1 NM_015751 2.10
Cluster 4 Cell cycle, DNA repair, Apoptosis
Cyr61 cysteine rich protein 61 NM_010516 6.60
Mtap9 microtubule-associated protein 9 Q3TRR0 2.64
Cluster 5 Enzyme, Kinase
Ppfia1 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF) XM_133979 2.74
Cluster 6 DNA binding protein, Transcription factor
Wdhd1 WD-repeat HMG-box DNA binding protein 1 NM_172598 2.04
Cluster 7 Miscellaneous
Prdm10 PR domain containing 10 Q3UTQ7 6.98
Tdrd3 Tudor domain containing 3 NM_172605 3.48
Mif4gd MIF4G domain containing NM_027162 2.16
Dnahc2 dynein, axonemal, heavy chain 2 O08826 2.09
At 12 h:
Cluster 1 Adhesion molecules, Cytoskeleton, Cell movement
Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 NM_011111 3.34
Cspg2 chondroitin sulfate proteoglycan 2 NM_019389 2.20
Mmp8 matrix metallopeptidase 8 NM_008611 2.18
Myo1d Myosin ID NM_177390 2.07
Cluster 2 Signal transmission, Transporter
Phip pleckstrin homology domain interacting protein Q32NY1 3.28
Cd38 CD38 antigen NM_007646 2.51
Rbp1 retinol binding protein 1, cellular NM_011254 2.28
Ap3s2 adaptor-related protein complex 3, sigma 2 subunit NM_009682 2.12
Golph4 golgi phosphoprotein 4 NM_175193 2.03
Cluster 3 Enzyme, Kinase
Dnm1l dynamin 1-like NM_152816 13.11
Wdfy3 WD repeat and FYVE domain containing 3 NM_172882 4.64
Acpp acid phosphatase, prostate NM_019807 2.18
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(Continued)
Apc adenomatosis polyposis coli NM_007462 2.15
Adhfe1 alcohol dehydrogenase, iron containing, 1 NM_175236 2.04
Cluster 4 Immune response
Ctla4 cytotoxic T-lymphocyte-associated protein 4 NM_009843 11.16
Cxcl7 chemokine (C-X-C motif) ligand 7 NM_023785 2.77
Cluster 5 RNA binding protein, Translation factor
Mrps5 mitochondrial ribosomal protein S5 NM_029963 2.20
Sf4 splicing factor 4 NM_027481 2.45
Cluster 6 DNA binding protein, Transcription factor
Asb2 ankyrin repeat and SOCS box-containing protein 2 NM_023049 2.75
Cluster 7 Miscellaneous
Dnahc2 dynein, axonemal, heavy chain 2 O08826 3.11
Ccdc89 coiled-coil domain containing 89 Q9DA73 2.01
aExpression ratio is defined as relative difference in expression with (+) compared to without (-) treatment with [BF/S+L/Ep] plant extract; (-) is DMSO vehicle
control.
Table 3 Down-regulation of genes in iBMDCs treated with [BF/S+L/Ep] for (A) 4 h or (B) 12 h compared to DMSO alone
Gene Title Accession Number Expression Ratio
a (+)/(-)
At 4 h:
Cluster 1 Adhesion molecules, Cytoskeleton, Cell movement
Cnn3 calponin 3, acidic NM_028044 0.13
Cdh10 cadherin 10 Q3UUB3 0.27
Itga6 Integrin alpha 6 NM_008397 0.50
Cluster 2 Cell cycle, DNA repair, Apoptosis
Sycp1 synaptonemal complex protein 1 NM_011516 0.25
Cluster 3 Enzyme, Kinase
Atad1 ATPase family, AAA domain containing 1 NM_026487 0.48
St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 6
NM_145838 0.45
Prkce Protein kinase C, epsilon NM_011104 0.47
Cluster 4 DNA binding protein, Transcription factor
Shprh SNF2 histone linker PHD RING helicase NM_172937 0.27
Zfp39 zinc finger protein 39 NM_011758 0.31
Cluster 5 Miscellaneous
Cep110 centrosomal protein 110 XM_981952 0.46
At 12 h:
Cluster 1 Adhesion molecules, cytoskeleton; cell movement
Cdh1 Cadherin 1 NM_009864 0.30
Gja1 gap junction membrane channel protein alpha 1 NM_010288 0.48
Cluster 2 Signal transmission, Transporter
Rab17 RAB17, member RAS oncogene family NM_008998 0.42
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novel proteins in BMDCs that respond to [BF/S+L/Ep]
Using 2D gel electrophoresis, we were able to routinely
obtain representative, high resolution, and highly repro-
ducible 2D protein profiles of mouse DCs as putative
proteomic maps (data not shown). Treatment of DCs
with [BF/S+L/Ep] at 75 μg/mL resulted in significant
changes in expression of some proteins in comparison
to the solvent-treated mouse DC samples. Differentially-
expressed proteins were then identified by MALDI-
TOF-MS and in some cases subsequently analyzed with
tandem MS/MS, after manual excision of these protein
spots from gels. A total of 23 different known protein
species were isolated and characterized by analysis with
MALDI-TOF-MS peptide mass fingerprinting (PMF).
Table 4 lists the changes in protein expression in DCs
treated with [BF/S+L/Ep] in vitro for 12 h, as compared
to solvent (vehicle) treatment (0.1% DMSO). Expression
of metabolism, cytoskeleton or NF-B-signaling related
proteins were most affected by [BF/S+L/Ep]. 2D gel
electrophoretic analyses showed increased levels of a
group of specific proteins, such as annexin A4 and
peroxiredoxin (Figure 4A). In contrast, the levels of
some other proteins, such as macrophage capping pro-
tein, were reduced (Figure 4B). These proteins, which
function in cytoskeleton organization, did not show a
detectable change in mRNA levels after [BF/S+L/Ep]
treatment.
5. Effect of [BF/S+L/Ep] extract on BMDC trafficking
The effect of [BF/S+L/Ep] on DC mobility was evaluated
by an in vivo DC trafficking assay. Primary BMDCs gen-
erated by in vitro culture were treated with 0.1%
DMSO, [BF/S+L/Ep] or LPS separately. Cells were then
stained with fluorescein isothiocyanate isomer I (a green
fluorescence dye) and administered to test mice via i.v.
injection. After 24 h, mice were sacrificed and DC moti-
lities in vivo were compared by scoring the presence
and number of DCs with green fluorescence dye in tis-
sue sections of inguinal lymph node, spleen and liver.
As seen in Figure 5, DCs treated with [BF/S+L/Ep]
showed a higher capacity to target lymph nodes and
spleen (Figure 5-d, e) than DMSO-treated DCs (Figure
5a, b; Figure 6). In comparison, DCs stimulated by LPS
showed a relatively higher capacity to target these
immune tissues, particularly the spleen (Figure 5-g, h).
Table 3: Down-regulation of genes in iBMDCs treated with [BF/S+L/Ep] for (A) 4 h or (B) 12 h compared to DMSO
alone (Continued)
Oscar osteoclast associated receptor NM_175632 0.44
Kcne3 Voltage-gated potassium channel, Isk-related subfamily, gene 3 NM_020574 0.49
Sla src-like adaptor NM_009192 0.50
Cluster 3 Enzyme, Kinase
Setd4 SET domain containing 4 NM_145482 0.32
Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 NM_026612 0.39
Acss1 acyl-CoA synthetase short-chain family member 1 NM_080575 0.40
Cluster 4 DNA binding protein, Transcription factor
Sox6 SRY-box containing gene 6 NM_011445 0.06
Dmc1h disrupted meiotic cDNA 1 homolog NM_010059 0.17
Nfxl1 nuclear transcription factor, X-box binding-like 1 Q3ULV1 0.36
Huwe1 HECT, UBA and WWE domain containing 1 NM_021523 0.41
Cluster 5 Protein metastasis
Fbxo36 F-box only protein 36 NM_025386 0.46
Cluster 6 RNA binding protein, Translation factor
Rbm14 RNA binding motif protein 14 NM_019869 0.50
Cluster 7 Miscellaneous
Speer4b spermatogenesis associated glutamate (E)-rich protein 4b NM_028561 0.19
Ccdc21 coiled-coil domain containing 21 NM_144527 0.47
Mgl1 macrophage galactose N-acetyl-galactosamine specific lectin 1 NM_010796 0.48
aExpression ratio is defined as relative difference in expression with (+) compared to without (-) treatment with [BF/S+L/Ep] plant extract; (−) is DMSO vehicle
control.
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trafficking of DCs throughout the tested experimental
period (Figure 5-c, f, i and 5l). These data indicate that
the Echinacea extract can stimulate enhanced migration
and mobility of DCs in vivo, in addition to its specific
effect on the transcriptome seen in vitro.
As shown in the insets of d and e in Figure 5, for [BF/
S+L/Ep]-treated DCs, the individual cellular events of
DC migration, are seen mainly as separated, single unit
fluorescent dots in the photomicrographs of test tissues,
and the fluorescence intensities are, in general, medium
to low. In contrast, the cellular behavior and light
Figure 3 Pathway analysis of representative genes that responded to [BF/S+L/Ep] treatment. A prototypical cell was constructed from 37
representative genes that responded to treatment with [BF/S+L/Ep] in vitro from 4 h to 12 h. A, Genes whose expression was up-regulated
(more than doubled) are colored red, and those whose expression was down-regulated (to less than half) are shown in green. Selected regions
of the network highlight several groups of genes. Group 1, Immune response related genes. Group 2, Adhesion molecules and cytoskeleton; cell
movement related genes. Group 3, Cell cycle, cell proliferation and apoptosis related genes. Gene networks were analyzed with the Ingenuity
Pathways program. B, The TRANSPATH Professional 7.1 database was searched to assess possible signaling pathways, networks or potential
interactions among the responsive genes/target molecules in DCs treated with [BF/S+L/Ep]. The 37 genes that were up- or down-regulated at
least 2-fold compared to controls were analyzed. Specifically, connections (hits) within 7 genes were employed as the parameter for the current
search. Five postulated key molecules/pathways; JNK2 (c-Jun NH2-terminal kinase 2), PP2C-a (protein phosphatase 2C-alpha), AKT (protein kinase
B), ERK (extracellular signal-related kinase) and MAPKAPK (MAPK-activated protein kinase 2) that may be activated by [BF/S+L/Ep] treatment are
predicted with arrows. The green rhombuses indicate the upstream transcription factors of responsive genes.
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samples (Figure 5-g and 5h) are more aggregated and
clumped together. In addition the colors are consider-
ably brighter than those seen for the [BF/S+L/Ep]-trea-
ted DCs. It was also observed that under in vitro test
conditions, the individual DCs treated with LPS became
enlarged in size, and thus could apparently absorb
higher levels of FITC-labeled dextran and also already
tended to aggregate together, as compared to DCs trea-
ted with [BF/S+L/Ep]. These effects of LPS may also
contribute to the observed results seen in trafficking
experiments, where more aggregated and brighter DCs
were detected in targeted tissues in LPS-treated DCs
than in cells treated with [BF/S+L/Ep].
The potential effect of [BF/S+L/Ep] on key cellular
physiological functions of DCs was further investigated
in an in vitro study, where the expression of specific che-
motaxis-related receptors for trafficking of DCs was ana-
lyzed by flow cytometry. BMDCs with or without LPS
stimulation were treated with [BF/S+L/Ep] for 24 h and
then assayed for expression of the three cell surface
markers CCR4, CCR5 and CCR7 (Figure 6), which are
known to play an important role in the mobility of DCs,
are expressed on DCs at distinguishable differentiation






cells were considered as immature and mature DC popu-
lations, respectively, as observed during their in vivo
maturation processes. Our data show that in vitro treat-
ment of DCs with [BF/S+L/Ep] significantly increases the
expression level of CCR5 on immature DCs (Figure 6 but
does not affect CCR5 expression on LPS-induced mature
DCs. Furthermore, we have observed that our herbal
extract treatment caused a suppressive effect on the
“endogenous” or “non-LPS-induced” generation of
mature DCs from immature DCs, as assessed by the
CCR7 activity measured for DMSO-treated and [BF/S+L/
Ep]-treated DCs (Figure 6). Considering our prior results
obtained both in vitro (i.e., DC maturation, Figure 1) and
in vivo (i.e., DC trafficking capacity, Figure 5), the data
shown in Figure 6 thus confirm our current key finding
that the [BF/S+L/Ep]-enhanced DC trafficking ability
Table 4 Differentially expressed proteins identified by MALDI-TOF-MS/MS analysis of 2D gel protein profiles of









54 Annexin A4 1.73 P97429 Signal transduction; cell communication
34 Peroxiredoxin 4 1.56 O08807 Metabolism; Energy pathways
82 Vimentin 1.13 P20152 Cell growth/maintenance
26 Alpha-actin-2 1.12 P62739 Cell growth/maintenance
23 Proliferin-1 1.1 P04095 Cell growth/maintenance
98 APAF1-interacting protein 1.09 Q9WVQ5 apoptosis
1 beta-actin 1.05 P99041 Cell growth/maintenance
58 Alpha-tubulin 1, 2, 4, 6 1.04 P68369... Cell growth/maintenance
79 Heat shock cognate 71 kDa protein 1.04 P63017 Protein metabolism
109 Solute carrier family 35 member E1 1.04 Q8CD26 Transport
55 Actin, cytoplasmic 1 (Beta-actin) 1.03 P60710 Cell growth/maintenance
88 YEATS domain-containing protein 4 0.96 Q9CR11 Regulation of nucleobase, nucleoside, nucleotide and
nucleic acid metabolism
6 Phenylalanyl-tRNA synthetase 0.92 Q99M01 Protein metabolism
41 Protein disulfide-isomerase A3
[Precursor]
0.92 P27773 Protein metabolism
38 Phosphoglycerate mutase 1 0.87 Q9DBJ1 Metabolism; Energy pathways
78 Heat shock protein 9, [Precursor] 0.84 P38647 Protein metabolism
56 F-actin capping protein alpha subunit 0.83 P47754 Cell growth/maintenance
13 Cathepsin S 0.81 O70370 Protein metabolism
91 Nucleoside diphosphate kinase 0.74 Q9WV84 Metabolism; Energy pathways
70 Alpha-enolase 0.73 P17182 Metabolism; Energy pathways
45 Macrophage capping protein 0.63 P24452 Cell growth/maintenance
192 Voltage-gated potassium channel
subfamily KQT member 2
0.46 Q9Z351 Transport
191 Protein tyrosine phosphatase
mitochondrial 1
0.34 Q66GT5 signal transduction; cell communication
aRelative protein level with or without [BF/S+L/Ep] (75 μg/mL), 0.1% DMSO as vehicle control.
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induced DC mobility.
Discussion
By using a combination of genomic and proteomic
experimental approaches, we investigated the ex vivo
effects of a candidate medicinal plant extract, [BF/S+L/
Ep], on the differentiation and modulation activities of
mouse BMDCs. This study extends our previous report
[9,10], where human DCs were used in a similar func-
tional genomics study. In addition to the ex vivo test
system, this study also examined the in vivo effect of
[BF/S+L/Ep] in experimental mice. Together, our cur-
rent and previous findings on both human and mouse
DCs, under in vitro as well as in vivo conditions, have
provided us with a comprehensive information base for
future translational research into potential clinical appli-
cation of [BF/S+L/Ep] as botanical drugs or nutritional
supplements. As demonstrated in Fig 2, our DNA
microarray test systems and the experimental cell cul-
ture replicate samples were highly reproducible and
consistent. We identified that close to 0.36% of the
genes from the BMDC genome are significantly affected
by treatment with [BF/S+L/Ep]. These differentially
expressed and responsive genes were mostly related to
cell adhesion and motility, immune response, signaling
molecules and specialty enzymes. Some of these genes
have been previously reported to be related to functions
of DCs, but a large portion are reported here for the
first time.
In this study, flow cytometry analysis on a number of
CD markers showed that expression of several mouse
DC surface markers was not significantly affected by
treatment with [BF/S+L/Ep], this finding was not consis-
tent with our previous data for human DCs [10]. This
result may suggest that specific biochemical and cellular
effects of herbal extract on DC maturation may vary
considerably between different mammalian species,
Figure 4 Proteomics analyses of E. purpurea phytocompound effects on mouse bone-marrow derived immature dendritic cells
(iBMDCs). Effect of Echinacea purpurea extract on differential protein expression in iBMDCs was evaluated by 2D gel electrophoretic analysis. 500
μg of total cell proteins from various treatments of iBMDCs were applied to pH 5-8 IPG strips. After isofocusing and 2D gel separation, SYPRO
Ruby was used to stain proteins. Images on gel were analyzed using PD-Quest software. Forty-two differentially-expressed proteins were trypsin-
digested in situ, and 23 protein spots were identified by MALDI-TOF MS, with their locations in gel assigned a number. These protein ID
numbers are listed in Table 4. A, Up-regulated and B, down-regulated protein spots are reported on a representative two-dimensional gel
corresponding to protein expression profile of iBMDCs. The expression ratios are shown in bold print. Gels shown here are representative of thee
independent experiments.
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or results from animal models into human application
need to be carefully addressed and considered with mul-
tiple references.
Immature DCs migrate from the blood to other tis-
sues where they take up and process target antigens.
Such DCs then subsequently migrate to the draining
lymphoid tissues, resulting in the priming of naïve T
cells following antigen presentation. During their migra-
tion, DCs are known to be involved in several adhesion
or cognition events. For instance, E-cadherin, which is
uniquely expressed by Langerhans DCs (LCs), permits
Figure 5 Effects of [BF/S+L/Ep] treatment on the trafficking activity of DCs. A, Two million BMDCs treated with DMSO (a-c), [BF/S+L/Ep]
(d-f) and LPS (g-i) were labeled with green fluorescence dye and injected into allogeneic mice. Tissues of control BALB/c mice which were
injected with DCs without fluorescence dye staining did not show significant green fluorescence spots, while the auto-fluorescence background
was rather low (j-l). After 24 h mice were sacrificed and DC mobility compared by detecting DCs with green fluorescence in peripheral lymph
nodes (a, d, g and j), spleen (b, e, h and k) and liver (c, f, I and l). Insets (d, e, g and h) show digitally amplified magnifications of treated DCs
exhibiting different cellular behaviors in tissue trafficking and different levels in fluorescent intensity. Samples of liver tissue were detecteda s
negative for fluorescence staining of DCs throughout the observation period.
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Page 12 of 18Figure 6 Effect of [BF/S+L/Ep] treatment (24 h) on the expression of CCR4, CCR5 and CCR7 proteins in BMDCs treated with or without
LPS stimulation. CCR5 and CCR7 are expressed as cell surface markers on DC at distinct differentiation stages and are known to play important




+ cells are considered as immature and mature DC populations, respectively. Populations of
them were compared by flow cytometry analysis.
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encounter can result in down-regulation of E-cadherin
that allows LC migration out of the skin [25]. The
release of collagenase by DCs can facilitate their migra-
tion through the basement membranes [26]. Our data
show that the gene expressing E-cadherin was down-
regulated in DCs at both 4 h and 12 h after treatment
with [BF/S+L/Ep]. Genes encoding for the cell adhesion
protein integrin alpha 6 (Itga6) and the cell signaling
protein gap junction membrane channel protein a1
(Gja1) were down-regulated at 4 h and 12 h post treat-
ment, respectively. Moreover, expression of specific col-
lagenases and proteases, such as Mmp-8 (Table 2),
Mmp-2,a n dMmp-14, and the macrophage elastase
Mmp-12 (data not shown in Table 2 and 3, due to rela-
tively low level slightly lower than 2 fold in fold change)
were appearently up-regulated after 12 h of treatment.
Taking these results together, and in conjunction with
the in vivo trafficking assay data (Figure 5), we suggest
that [BF/S+L/Ep] phytoextract can confer a modulatory
effect on cell mobility of mouse BMDCs. In future stu-
dies it will be important and interesting to determine
whether such an in vivo effect is also observed for
human DCs, and thus for potential clinical application.
In general, various major inflammatory and immuno-
modulatory cytokines such as IL-1, TNF-a,I F N g,I L - 4 ,
IL-5, IL-6, IL-13, and IL-17, which are readily induced by
injury or infection, are known to stimulate the produc-
tion of a spectrum of different chemokines though med-
iation via their respective receptors [27-29]. For instance,
it is known that mice deficient in CCR2, the only known
CCL2 receptor, have impaired Th1 responses [30], owing
to a reduction of monocyte trafficking to the sites of
inflammation [31]. In this study we show that a number
of immune-related genes were up-regulated after 4 h and
12 h treatment of [BF/S+L/Ep]. These include genes
encoding angiomotin (Amot), which is involved in cell
movement and embryogenesis [32], chemokine (C-X-C
motif) ligand 2 (Cxcl5), pro-platelet basic protein (Cxcl7),
involved in chemokine activity and leukocyte transen-
dothelial migration [33], immunoresponsive gene 1 (Irg1)
and cytotoxic T-lymphocyte-associated protein 4 (Ctla4).
These results suggest that [BF/S+L/Ep] may modify the
chemotactic behavior of mouse DCs. Since some respon-
sive chemokines such as CXCL5 and CXCL7, which we
detected here in test DCs, are currently not well defined
in terms of cellular function and biochemistry, further
studies are needed to examine how [BF/S+L/Ep] can
exert an effect on the secretion of these chemokines and
to find out whether these chemokines do play a role in
the chemoattraction and trafficking of treated DCs in the
mouse system. On the other hand, our in vitro study did
allow us to show that phenotypic expression of chemo-
taxis-related receptor proteins, including CCR5 and
CCR7, can be significantly regulated in test mouse DCs
treated with [BF/S+L/Ep] (Figure 6). Whether or not spe-
cific chemotaxis-related receptors, such as CCR5, can
mechanistically modulate the [BF/S+L/Ep]-enhanced DC
mobility will also require further investigations. Unlike
o u rp r e v i o u sf i n d i n g so nh u m a nD C s[ 9 ] ,[ B F / S + L / E p ]
treatment had a readily distinguishable and a slower level
effect on the expression of immune-related genes in
mouse BMDCs. These results again suggest, like the
effects observed for cell surface marker proteins, the
immunomodulatory effects of phytocompounds from
Echinacea extracts apparently could also differ substan-
tially between humans and mice.
It is well known that DCs are the principal antigen
presenting cells (APCs) for T-cell priming [34]. It is
important to note, however, that DCs are also involved
in the induction of central and peripheral tolerance [35].
One protein, called cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4), is known as an immunomodulatory
membrane molecule. By decreasing T-cell responsive-
ness and raising the threshold for T-cell activation,
CTLA-4 plays a critical role in the maintenance of per-
ipheral T-cell tolerance [36,37]. Here, we found that the
expression of Ctla4 was drastically up-regulated in DCs
after 12 h of treatment with [BF/S+L/Ep]. Whether the
CTLA-4 signaling system for DCs were also affected by
our test phyto-compound and could in turn further
affect T cell or other DC associated immunities would
need to be further analyzed in future studies.
In human DCs, we showed that [BF/S+L/Ep] can effect
the expression of specific cytoskeleton proteins, including
macrophage-capping protein, cofilin, profilin, F-actin
capping protein b subunit, and laminin A/C [10]. In the
present study using mouse DC cells, our 2D gel electro-
phoretic analyses on DC proteins revealed that expression
of several cytoskeleton-related proteins, such as alpha-
actin-2 and F-actin capping protein alpha and macrophage
capping protein, were also altered by [BF/S+L/Ep]. These
results together suggest that Ep phytocompound extract
modulates specific cytoskeleton functions, which are
known to play a role in testing DCs to specific immune
processes. A group of specific proteins, such as annexin
A4, which can reversibly modify various membrane prop-
erties (e.g., fluidity and permeability), anchoring of cytos-
keletal elements, aggregation of vesicles, and the
regulation of ion conductance [38], and peroxiredoxin 4,
which exhibits thioredoxin-dependent peroxidase activity
and regulates the activation of the transcription factor NF-
B [39], were up-regulated in mouse DCs after treatment
with [BF/S+L/Ep] (Figure 4B). These results suggest again
that [BF/S+L/Ep] may affect the cell mobility and NF-B
signaling of BMDCs. Moreover, expression of several cel-
lular metabolism-related proteins, including vimentin, pro-
liferin-1 precursor-1, -2, -3, phenylalanyl-tRNA synthetase,
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sphate kinase and alpha-enolase were also affecteded by
[BF/S+L/Ep] treatment (Table 4). Whether these changes
are functionally related to specific cellular and molecular
activities of mouse DCs needs to be further investigated.
Previous studies have demonstrated that specific alky-
lamides of E. purpurea can effectively stimulate macro-
phage function in healthy rats or RAW 264.7 cells
[40,41]. In addition, specific in vitro effects of Echinacea
extract and several of its phytochemical components on
NF-Be x p r e s s i o ni nJ u r k a tc e lls (a human T-cell line)
have been reported [42]. Recently we reported that phy-
tocompounds from E. purpurea extracts could affect
specific cell-surface marker expressions and cytoskeleton
rearrangement in treated human DCs [9,10]. These find-
ings suggest that a spectrum of specific immunomodula-
tory effects in DCs can be modulated by phytochemicals
from E. purpurea at the cellular level. It is interesting to
find that in this study, although the specific groups of
responsive RNA transcripts and proteins seem to differ
substantially from the results obtained from our pre-
vious studies on human DCs, the end result in terms of
cellular functions seems to suggest that many of them,
such as cytoskeleton-associated gene or protein expres-
sion can in fact be quite similar, and this provides valu-
able correlated information for future evaluations of
the various molecular mechanisms of these effects. The
in vivo DC trafficking results obtained in this study may
further suggest the importance of the mobility and
cytoskeletal components of the differentially expressed
transcriptome for future evaluation of pharmaco-geno-
mics activities in a mouse DC system in vivo. Besides,
we believe that our current transient labeling system for
DCs may provide future application to translational
research on phytochemical or herbal medicinal effect
on DCs.
Conclusion
In this study, data obtained from both in vitro transcrip-
tomic analyses and in vivo DC trafficking assays suggested
that [BF/S+L/Ep] treatment can affect DC mobility. The
effects of this bioactive herbal extract on expression of
cytoskeleton-related RNA transcripts as well as on differ-
ential protein expressions related to cell adherence and
other DC functions add complementary and supportive
information to our previous studies on human DCs [9,10].
Taken together, our research shows that this candidate
herbal medicine may cause drastic modulatory effects on
specific immune cells (DCs) by regulating key cellular
behaviors. In addition, bioinformatics studies from this
and our previous study [10] have revealed a group of can-
didate target molecules and signaling networks, for exam-
ple the JNK, PP2C-a, AKT and MAPKAPK pathways, that
we believe warrant future systematic studies as key targets
for immunomodulatory phytomedicines, via mediation
with dendritic cells.
Methods
Plant materials and plant extract preparations and
fractionations
Echinacea purpurea plants grown to the flowering stages
were harvested from a reputable organic farm in Puli,
Nantou County, Taiwan as previously described [9].
Stem and leaf tissues of fresh plants were extracted at
room temperature by imbibition in 70% aqueous ethanol
for 35 days, mimicking a traditional Chinese medicine
(TCM) preparation protocol. The final 70% ethanol-
soluble fraction was dried under vacuum, re-suspended
and dissolved in 1 liter of water and then successively par-
titioned with ethyl acetate (1 L × 3 times) and n-butanol
(1 L × 3 times) to yield three subfractions designated as
the EA, BuOH and water (H2O) fractions of the (S+L)
extract [10,43]. The percentage yield for the BuOH frac-
tion of the stem and leaf tissue extract [BF/S+L/Ep] was
7.23% of the 70% ethanol extracts by dry weight.
Culture of DCs from bone marrow
DCs were generated by using the method described by
Inaba et al. [44]. Six-week-old female BALB/c (H-2Kd,
I-Ad) mice were purchased from the National Labora-
tory Animal Center and kept under specific pathogen
free (SPF) conditions. Femurs and tibiae were removed
after euthanasia and the bone marrow was flushed with
RPMI-1640 medium using a syringe with a 0.45-mm
needle. Red blood cells in suspension were lysed with
ACK lysing buffer (150 mM NH4Cl, 1.0 mM KHCO3,
0.1 mM EDTA) for 5 min. Bone marrow cells were sus-
pended at concentration of 1×10
7cells/30 ml complete
media (CM, RPMI-1640 supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 1% of nones-
sential amino acids and 100 U/mL penicillin and 100
μg/mL streptomycin). Test cells were cultured for up to
9d a y sw i t h1 0 0 0U / m Lo fG M - C S Fa t3 7 ° C ,5 %C O 2.
On day 3, two-thirds of the medium was removed and
30 mL fresh medium with GM-CSF was added to the
cells. On day 6, culture plates were gently swirled and
the floating and loosely adherent cells were discarded.
Aliquots of 75% of culture media were replaced with
fresh culture medium with GM-CSF. On day 9, non-
adherent cells were collected and used as the immature
DC population for subsequent tests and analyses.
Treatment of DCs with E. purpurea extract
[BF/S+L/Ep] was dissolved in 100% pure and endotoxin-
free dimethyl sulfoxide (DMSO). The working concen-
trations of each extract sample were prepared by serial
dilutions to 75 μg/mL. This dosage for stimulation of
DCs was chosen based on our results obtained by MTT
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50, 75, 100, 500 μg/ml resulted in a cell viability, on
average, of 100%, 102%, 107%, 104%, 99% and 73%,
respectively, as compared to the vehicle control (data
not shown). Treatment at 100 μg/ml [BF/S+L/Ep] might
cause some limited cytotoxicity, whereas the dosage of
75 μg/ml does not result in any cytotoxic effects. The
final DMSO concentration reached 0.1% in each DC
culture. An aliquot of a 0.1% DMSO solution in med-
ium only was thus used as a vehicle (negative) control.
LPS from Escherichia coli (serotype 055:B5) was pur-
chased from Sigma (St. Louis, MO) and used for cell
activation or quality control at 1 μg/mL.
Flow cytometric analysis
All cell samples were stained using a direct immuno-
fluorescence staining method. For each step of the stain-
ing, 2 × 10
5 cells were treated with specific antibodies
for 30 min at 4°C in 45 μL of phosphate-buffered saline
(PBS) containing 2% bovine serum albumin (BSA). Test
cells of each experimental group were first incubated
with purified anti-CD16/CD32 antibody (mouse IgG2a,
93) for 10 minutes on ice. Fluorescein isothiocyanate
(FITC)- or phycoerythin (PE)-labeled monoclonal anti-
bodies were then used for staining of MHC class II
(I-Ab, mouse IgG2a, 2G9), CCR4 (mouse IgG, 2G12),
CCR5 (mouse IgG, HM-CCR5), CCR7 (mouse IgG2a,
4B12), CD40 (mouse IgG, HM40-3), CD80 (mouse IgM,
16-10A1), CD86 (mouse IgG, GL-1) and CD11c (mouse
IgG, N418) on test cells. All antibodies were purchased
from Biolegend (San Diego, CA). After cell samples
were incubated with test antibody at 4°C for 40 min,
cells were washed twice with PBS and fixed with 1%
paraformaldehyde. Test cells were then analyzed in a
Coulter EPICS XL flow cytometer (Beckman/Coulter).
DNA microarray analysis for gene expression
Total RNA was isolated using TRIzol (Invitrogen)
according to the manufacturer’s instruction and used to
generate cRNA targets. A total of 7 μg of RNA from each
sample was used to synthesize the first strand cDNA
using T7-Oligo (dT) primer and T7 RNA polymerase by
in vitro transcription (IVT) reaction. The biotinylated
cRNA products were then cleaned up according to the
Affymetrix protocol. An aliquot of 15 μgo fR N Ap e r
sample was then hybridized to a Affymetrix gene chip,
the mouse Genome 430 2.0 array, containing 45,101 pro-
besets and variants from over 34,000 well-characterized
mouse genes, using a standard protocol suggested by the
Affymetrix menu. Images of the array signals were col-
lected on Affymetrix scanners. A total of 8 hybridizations
were performed for immature DCs, while each time
point and treatment was analyzed in duplicates on sepa-
rate chips. Standard Pearson correlation coefficients were
u s e dt od e t e r m i n et h ec o n s i s t e n c yo fg e n ee x p r e s s i o ni n
each replicate Affymetrix array.










Data was analyzed using Spotfire software, which
includes algorithms that determine whether a gene is
absent or present and whether the expression level of a
gene in an experimental sample is significantly increased
or decreased relative to a control sample. Changes in
expression levels are presented as averages of log2 (BF/
S+L/Ep treatment)/(DMSO treatment). The microarray
data have been deposited to the Gene Expression Omni-
bus database at NCBI (GEO; http://www.ncbi.nlm.nih.
gov/projects/geo/) under the accession number
GSE19369.
2-D gel electrophoresis and image analysis
Total cellular proteins of immature dendritic cells
were prepared using 0.3 mL of sample buffer [7 M urea
(Bio-Rad), 2 M thiourea, 4% CHAPS (Sigma), 10% 1,4-
dithioerythitol (Merck, Frankfurt, Germany), 2% Phama-
lyte 3-10] by vortexing for 1 h and then collecting the
protein supernatants by 55,000 RPM and for 1 h. Protein
concentration was determined by using a protein assay
kit (Bio-Rad, Hercules, CA). 2-D gel electrophoresis was
carried out using the Bio-Rad Protean IEF cell and Pro-
tean electrophoresis cell system as described previously
[10,45] with modifications. Digitalized gel images were
analyzed with 2-D analysis software (PD Quest, Bio-Rad)
as previously described [10]. The image with the highest
number of spots was selected as the master gel. Automa-
tically detected images of protein spots in test gels were
then manually edited to include the low intensity spots
and correct for spot artifacts. For the match set contain-
ing images with pI 5-8, the spot volume (intensity inte-
grated over the spot area) was normalized by the volume
of total spots in the gel. The data was then exported to
Microsoft Excel.
Protein identification by MALDI-TOF-MS
Protein identification was performed as described pre-
viously [10]. Briefly, each gel slice was cut into small
pieces with a scalpel. Reduction was achieved with 10
mM DTT at 57°C for 1 h. Alkylation reaction was per-
formed with 55 mM iodoacetamide for 1 h at room
temperature in the dark. Gel spots were then washed
for 10 min alternately with 25 mM NH4HCO3 and acet-
onitrile. Gel pieces were completely dried using a Speed
Vac. The dried gel pieces were then immersed in three
volumes of trypsin solution (V5111; Promega, Madison,
WI), at 20 ng/mL in 25 mM NH4HCO3 (freshly diluted).
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tryptic peptides were extracted from test gel pieces in 5
mL of 70% acetonitrile 5% HCOOH by sonication. The
supernatant was dried under a Speed Vac and 6 μLo f
1% HCOOH was then added to each test sample. Pro-
tein identification using MALDI-Q-TOF-MS analysis
was performed by the Proteomics Core Facility of the
Institute of Biological Chemistry, Academia Sinica, Tai-
wan [10]. The MS data with monoisotopic peptide
masses were searched against the NCBI protein database
using the MASCOT search engine (Matrix Science,
London, UK).
DC trafficking in vivo
To analyze the migration of ex-vivo cultured DCs under
in vivo experimental conditions in test mice, 1 × 10
6
cultured DCs were labeled with fluorescein isothiocyanate
isomer I (See Figure 5; green fluorescence dye) at 300 μg/
mL at 37°C for 20 min, cells were then washed three times
with PBS and subsequently injected into the tail vein of
syngeneic BALB/c mice. Fresh lymph node (LN), spleen
and liver tissues were harvested and frozen tissue sections
of 12 μm in thickness were mounted on precleaned micro-
scope slides (Superfrost/Plus; Fisher Scientific, Pittsburgh,
PA), and stored at -80°C. To retain the fluorescent signal,
the tissue sections were pretreated with 4% paraformalde-
hyde at room temperature. Tissue sections were first incu-
bated with blocking solution (2% fetal calf serum in PBS)
for 10 min. Nuclear staining was then performed with 4,6-
diamidino-2-phenylindole (DAPI) and followed by wash-
ing with 1 × PBS (2 × 5 min each). Tissue sections were
then mounted with 50% glycerol in H2O with coverslips.
Fluorescence microscopy evaluation of immunostained
frozen sections was performed using a Zeiss Axiovert
200 M microscope (Carl Zeiss, Heidelberg, Germany).
Microscopy photos and images were captured with a digi-
tal camera (Orca ER; Hamamatsu) and processed using
Axiovision 4.6.3 (Carl Zeiss). The number of individually
florescent spot as test cells was then scored for compara-
tive analysis and the data was exported to Microsoft Excel.
Pathway analysis of representative genes involved in/
associated with effects of [BF/S+L/Ep] on BMDCs
Using a Web-based entry tool developed by Ingenuity
Systems [46], findings presented in peer-reviewed scienti-
fic publications were systematically encoded into ontol-
ogy by content and modeling experts. A molecular
network of direct physical, transcriptional and enzymatic
interactions was observed between mammalian ortho-
logs. For a better understanding of the temporal response
of gene expression in the immune system, we con-
structed a prototypical cell showing the possible candi-
date signaling pathways, containing 35 genes (>2-fold
change) responding to treatment with [BF/S+L/Ep]. The
candidate genes of interest also were keyed into TRANS-
PATH professional database, version 7.1, (Biobase Biolo-
gical Databases GmbH, Germany) to identify possible
target molecules and signaling pathways, using four hier-
archical levels of regulation [9,10].
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